Literature DB >> 10194140

Transition of polycythemia vera to chronic neutrophilic leukemia.

T Higuchi1, R Oba, M Endo, H Harada, H Mori, H Niikura, M Omine, K Fujita.   

Abstract

Two cases of polycythemia vera (PV) had transition to a hematological condition compatible with chronic neutrophilic leukemia (CNL) 17 and 8 years after diagnosis, respectively. One patient was treated with carboquone followed by hydroxyurea (HU) and the other with HU during PV phase. On transition, both had neutrophilia with white blood cell count above 40,000/microl, elevated neutrophil alkaline phosphatase activity, splenomegaly, normal karyotype without bcr-abl rearrangement. Busulfan was temporally effective in controlling the neutrophil count. However, one patient progressed to the so-called spent phase and the other subsequently had multiple transitions between PV and CNL. These cases may represent a form of uncommon evolution of PV and support the contention that CNL is a type of myeloproliferative disorder and that at least some CNL cases have derangement at the hematopoietic stem cell level.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10194140     DOI: 10.3109/10428199909093744

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  4 in total

Review 1.  [Myeloproliferative neoplasms: histopathological and molecular pathological diagnosis].

Authors:  K Hussein; G Büsche; J Schlue; U Lehmann; H Kreipe
Journal:  Pathologe       Date:  2012-11       Impact factor: 1.011

Review 2.  [Precursors of acute leukemia: myelodysplastic syndromes and myeloproliferative neoplasms].

Authors:  H H Kreipe
Journal:  Pathologe       Date:  2011-11       Impact factor: 1.011

3.  A case of transition of polycythemia vera to chronic neutrophilic leukemia.

Authors:  Seung Soon Lee; Joon Ho Moon; Jun-Wook Ha; Young Kyung Lee; Jin Seok Ahn; Dae Young Zang; Hyo Jung Kim
Journal:  Korean J Intern Med       Date:  2004-12       Impact factor: 2.884

Review 4.  Chronic neutrophilic leukemia: new science and new diagnostic criteria.

Authors:  Natasha Szuber; Ayalew Tefferi
Journal:  Blood Cancer J       Date:  2018-02-13       Impact factor: 11.037

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.